Table of Contents
EXECUTIVE SUMMARY
- Strategic scoping and focus
- Datamonitor insight into the molecular targeted cancer therapies market
- Related reports
- Upcoming related reports
MARKET DEFINITION
- Market definition for this report
- Molecular targeted cancer therapies by ATC class
MARKET OVERVIEW
- Seven major markets
- Current and future market overview
- Opportunities and threats
- US
- Current and future market assessment
- Opportunities and threats
- Japan
- Current and future market assessment
- Opportunities and threats
- Five major European markets (5EU)
- Current and future market assessment
- Opportunities and threats
- France
- Current and future market assessment
- Germany
- Current and future market assessment
- Italy
- Current and future market assessment
- Spain
- Current and future market assessment
- UK
- Current and future market assessment
- Rest of the world snapshot
- Current market assessment
- Opportunities and threats
BRAND DYNAMICS
- Overview of competitive landscape
- Avastin, Rituxan and Herceptin will maintain their 2008 position as the
top 3 molecular targeted cancer therapy brands in 2018
- Drivers of brand choice
- Efficacy and toxicity of a drug are the most important drivers of
molecular targeted cancer therapy brand choice
- Trends in marketing strategies
- Marketing strategy for leading brands
- Leading molecular targeted cancer therapy brands
- Avastin (bevacizumab; Roche/Chugai)
- Rituxan (rituximab; Biogen Idec/Roche/Chugai/Zenyaku Kogyo)
- Herceptin (trastuzumab; Roche/Chugai)
- Gleevec (imatinib; Novartis)
- Erbitux (cetuximab; Eli Lilly/Bristol-Myers Squibb/Merck KGaA)
KEY DEVELOPERS
- Strategic overview
- Trends in corporate strategy
- Developers of molecular targeted cancer therapies have turned their
attention to indication expansion across multiple tumor types
- Partnership with a large company has been a successful strategy for
several small developers of molecular targeted cancer therapies
- Roche
- Corporate strategy
- Molecular targeted cancer therapies portfolio assessment
- Novartis
- Corporate strategy
- Molecular targeted cancer therapies portfolio assessment
- Portfolio assessment of other leading companies
CASE STUDIES
- Embracing companion diagnostics will enhance the commercial potential of
molecular targeted cancer therapies
- Herceptin: companion diagnostics can help a company to establish and
dominate a market segment
- Erbitux/Vectibix: companion diagnostics will offset negative impact of
label restriction and facilitate indication expansion
- Erbitux: companion diagnostics are useful in demonstrating
cost-effectiveness
- Iressa: companion diagnostics set to play an important role in the
turnaround of a troubled drug' s fortunes
BIBLIOGRAPHY
- Journal papers
- Websites
- Datamonitor reports
- Other
APPENDIX A - MARKET ASSUMPTIONS
- New product launches
- Patent expiries
- Data definitions, limitations and assumptions
- Standard units
- Japanese market data
- Rest of the World
- Derivation of sales forecasts and pricing trends
- Forecast methodology
- Report methodology
APPENDIX B
TABLES
- Table: Definition of the molecular targeted therapies market, 2009
- Table: Sales and growth of molecular targeted cancer therapy drug classes
in the seven major markets, 2008 - 2018
- Table: Key events impacting the molecular targeted cancer therapies
market, 2008 - 2018
- Table: Top 5 branded molecular targeted cancer therapies in the seven
major markets in 2008 and 2018
- Table: Molecular targeted cancer therapy sales forecasts in the seven
major markets ($m), 2008 - 2018
- Table: Summary of opportunities and threats impacting the molecular
targeted cancer therapies market across the seven major markets, 2009 - 2018
- Table: Sales and growth of molecular targeted cancer therapy drug classes
in the US, 2008 - 2018
- Table: Top 5 branded molecular targeted cancer therapies in the US in 2008
and 2018
- Table: Molecular targeted cancer therapy sales forecasts in the US ($m),
2008 - 2018
- Table: Summary of opportunities and threats impacting the molecular
targeted cancer therapies market in the US, 2009 - 2018
- Table: Sales and growth of molecular targeted cancer therapy drug classes
in Japan, 2008 - 2018
- Table: Top 5 branded molecular targeted cancer therapies in Japan in 2008
and 2018
- Table: Molecular targeted cancer therapy sales forecasts in Japan major
markets ($m), 2008 - 2018
- Table: Summary of opportunities and threats impacting the molecular
targeted cancer therapies market in Japan, 2009 - 2018
- Table: Sales and growth of molecular targeted cancer therapy drug classes
in the five major European markets, 2008 - 2018
- Table: Top 5 branded molecular targeted cancer therapies in the five major
European markets in 2008 and 2018
- Table: Molecular targeted cancer therapy sales forecasts in the five major
European markets ($m), 2008 - 2018
- Table: Summary of opportunities and threats impacting the molecular
targeted cancer therapies market in the five major European markets, 2009 -
2018
- Table: Top 5 branded molecular targeted cancer therapies in France in 2008
and 2018
- Table: Molecular targeted cancer therapy sales forecasts in France ($m),
2008 - 2018
- Table: Top 5 branded molecular targeted cancer therapies in Germany in
2008 and 2018
- Table: Molecular targeted cancer therapy sales forecasts in Germany ($m),
2008 - 2018
- Table: Top 5 branded molecular targeted cancer therapies in Italy in 2008
and 2018
- Table: Molecular targeted cancer therapy sales forecasts in Italy ($m),
2008 - 2018
- Table: Top 5 branded molecular targeted cancer therapies in Spain in 2008
and 2018
- Table: Molecular targeted cancer therapy sales forecasts in Spain ($m),
2008 - 2018
- Table: Top 5 branded molecular targeted cancer therapies in the UK in 2008
and 2018
- Table: Molecular targeted cancer therapy sales forecasts in the UK ($m),
2008 - 2018
- Table: Comparison of molecular targeted cancer therapy drug class sales
($m) in the seven major markets and Rest of the World, 2008
- Table: Comparison of molecular targeted cancer therapy sales ($m) in the
BRIC countries, Australia and Canada, 2008
- Table: Branded molecular targeted cancer therapy drug sales in the seven
major markets ($m), 2008 - 2018
- Table: Marketing strategies employed by the companies behind the top four
molecular targeted cancer therapy brands, 2009
- Table: Avastin - drug profile, 2009
- Table: Impacting factors on the revenues of Avastin, 2009 - 2018
- Table: Rituxan - drug profile, 2009
- Table: Impacting factors on the revenues of Rituxan, 2009 - 2018
- Table: Herceptin - drug profile, 2009
- Table: Impacting factors on the revenues of Herceptin, 2009 - 2018
- Table: Gleevec - drug profile, 2009
- Table: Impacting factors on the revenues of Gleevec, 2009 - 2018
- Table: Erbitux - drug profile, 2009
- Table: Impacting factors on the revenues of Erbitux, 2009 - 2018
- Table: Leading companies in the molecular targeted cancer therapies market
by sales in the seven major markets, 2008 - 2018
- Table: Assessment of Roche' s molecular targeted cancer therapies
portfolio, 2009
- Table: Assessment of Novartis' s molecular targeted cancer therapies
portfolio, 2009
- Table: Assessment of Bristol-Myers Squibb' s molecular targeted cancer
therapies portfolio, 2009
- Table: Assessment of Celgene' s molecular targeted cancer therapies
portfolio, 2009
- Table: Assessment of Pfizer' s molecular targeted cancer therapies
portfolio, 2009
- Table: Commercially available companion diagnostics for molecular targeted
cancer therapies, 2009
- Table: Regional launch dates for new molecular targeted therapies in the
seven major markets, 2008 - 2018
- Table: Patent expiry dates for the approved molecular targeted cancer
therapies in the seven major pharmaceutical markets, 2008 - 2018
FIGURES
- Figure: Molecular targeted cancer therapy sales ($m) by country in the
seven major markets, 2008 - 2018
- Figure: Molecular targeted cancer therapy sales ($m) by drug class in the
seven major markets, 2008 - 2018
- Figure: Performance of leading molecular targeted cancer therapy brands in
the seven major markets, 2008 versus 2018
- Figure: Seven major market population aged 60 and over, 2000 - 2050
- Figure: Global therapy sales ($m), 2007 - 2012
- Figure: Molecular targeted cancer therapy sales ($m) by drug class in the
US, 2008 - 2018
- Figure: Molecular targeted cancer therapy sales ($m) by drug class in
Japan, 2008 - 2018
- Figure: Molecular targeted cancer therapy sales ($m) by drug class in the
five major European markets, 2008 - 2018
- Figure: Molecular targeted cancer therapy sales ($m) by drug class in
France, 2008 - 2018
- Figure: Molecular targeted cancer therapy sales ($m) by drug class in
Germany, 2008 - 2018
- Figure: Molecular targeted cancer therapy sales ($m) by drug class in
Italy, 2008 - 2018
- Figure: Molecular targeted cancer therapy sales ($m) by drug class in
Spain, 2008 - 2018
- Figure: Molecular targeted cancer therapy sales ($m) by drug class in the
UK, 2008 - 2018
- Figure: Rest of the world versus seven major market sales split for sales
of molecular targeted cancer therapies ($m), 2008
- Figure: Drivers of brand choice for molecular targeted cancer therapies in
cancer
- Figure: Avastin SWOT analysis, 2009
- Figure: Avastin forecast sales ($m) by country in the seven major markets,
2008 - 2018
- Figure: Rituxan SWOT analysis, 2009
- Figure: Rituxan forecast sales ($m) by country in the seven major markets,
2008 - 2018
- Figure: Herceptin SWOT analysis, 2009
- Figure: Herceptin forecast sales ($m) by country in the seven major
markets, 2008 - 2018
- Figure: Gleevec SWOT analysis, 2009
- Figure: Gleevec forecast sales ($m) by country in the seven major markets,
2008 - 2018
- Figure: Erbitux SWOT analysis, 2009
- Figure: Erbitux forecast sales ($m) by country in the seven major markets,
2008 - 2018
|
Related Report
|
View Cart
